Robeco Institutional Asset Management B.V. increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 559.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 641,718 shares of the biotechnology company's stock after acquiring an additional 544,457 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.33% of BioMarin Pharmaceutical worth $35,275,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Dodge & Cox grew its holdings in BioMarin Pharmaceutical by 1.4% during the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company's stock valued at $1,057,186,000 after buying an additional 209,005 shares in the last quarter. AQR Capital Management LLC grew its holdings in BioMarin Pharmaceutical by 127.9% during the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company's stock valued at $203,987,000 after buying an additional 1,642,206 shares in the last quarter. Nuveen LLC purchased a new position in BioMarin Pharmaceutical during the 1st quarter valued at about $184,475,000. Goldman Sachs Group Inc. grew its holdings in BioMarin Pharmaceutical by 212.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock valued at $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in BioMarin Pharmaceutical by 7.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company's stock valued at $108,319,000 after buying an additional 108,806 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have weighed in on BMRN shares. HC Wainwright started coverage on BioMarin Pharmaceutical in a report on Monday, September 8th. They set a "neutral" rating and a $60.00 target price for the company. Wolfe Research set a $95.00 target price on BioMarin Pharmaceutical and gave the company an "outperform" rating in a report on Tuesday, July 15th. JPMorgan Chase & Co. boosted their price objective on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Raymond James Financial initiated coverage on BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price objective for the company. Finally, UBS Group boosted their price objective on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $92.95.
Read Our Latest Stock Analysis on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
NASDAQ:BMRN opened at $55.43 on Friday. The business has a 50 day moving average of $56.77 and a 200 day moving average of $58.78. The company has a market capitalization of $10.64 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 0.71 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 1-year low of $52.47 and a 1-year high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60.
BioMarin Pharmaceutical Company Profile
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
